Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain

a technology of dimethylaminopropane and neuropathic pain, which is applied in the field of use of 1phenyl3dimethylaminopropane compounds, can solve the problems of not being effective at all, not being easy to achieve, and only being slightly effective, so as to achieve high effective treatment of neuropathic pain

Inactive Publication Date: 2008-10-30
GRUNENTHAL GMBH
View PDF2 Cites 46 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]A further object of the invention was to provide a new method of effectively treating neuropathic pain without excessive side effects.
[0013]It has now surprisingly been found that the compounds disclosed hereinbelow are highly effective in treating neuropathic pain, and surprisingly particularly effective in treating polyneuropathic and diabetic neuropathic pain.

Problems solved by technology

The achievement of these objects is complicated by the fact that a large to overwhelming proportion of the substances effective in treating nociceptive pain—such as acute pain—are not effective at all, or are only slightly effective, in treating neuropathic pain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain
  • Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain
  • Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain

Examples

Experimental program
Comparison scheme
Effect test

example 0

Tested Substances

[0089]The following compounds were tested and are hereinafter correspondingly abbreviated as compound (or Comp.) 1, etc. in Table 1:

TABLE 1Name:Compound(2RS,3RS)-1-dimethylamino-3-(3-methoxyphenyl)-2-1methylpentan-3-ol: hydrochloride(2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-2methylpentan-3-ol; hydrochloride(2R,3R)-1-dimethylamino-3-(3-methoxyphenyl)-2-3methylpentan-3-ol; hydrochloride(1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-5dimethylpropyl)-phenol; hydrochloride(1S,2S)-3-(3-dimethylamino-1-hydroxy-1,2-6dimethylpropyl)phenol; hydrochloride(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-7dimethylpropyl)phenol; hydrochloride(2RS,3RS)-3-(difluoromethylphenyl)-1-dimethylamino-2-8methylpentan-3-ol; hydrochloride(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-9phenol; hydrochloride(1S,2S)-3-(3-dimethylamino-1-ethyl-2-10methylpropyl)phenol; hydrochloride3-(3-dimethylamino-1,2-dimethylpropenyl)-phenol;14hydrochlorideAdditionally:MorphineMorGabapentinGBP

example 1

Bennett

Neuropathic Pain in Rats

[0090]The effectiveness in treating neuropathic pain was investigated in the Bennett model (chronic constriction injury; Bennett and Xie, 1988, Pain 33: 87-107).

[0091]Sprague-Dawley rats weighing 140-160 g are provided with four loose ligatures of the right sciatic nerve under nembutal narcosis. The animals develop a hypersensitivity in the paw innervated by the damaged nerve, which after a healing phase of one week is quantified over about four weeks by means of a 4° C. cold metal plate (cold allodynia). The animals are observed for two minutes on this plate and the number of retractive movements of the damaged paw are measured. The effect of the substance is determined with reference to the base value before application of the substance, at four different times over a period of one hour(15, 30, 45 and 60 minutes after application) and the resultant area under the curve (AUD) as well as the inhibition of cold allodynia at the individual measurement po...

example 2

Chung

In Vivo Experiments According to Chung

[0093]Spinal nerve ligatures according to Kim & Chung (1992 Pain 50, 355-363) were applied to the left L5 / L6 spinal nerves of male Spraque-Dawley rats. Four to six days after the operation the tactile threshold baseline (withdrawal threshold) was measured on the ipsilateral and contralateral rear paw by an electronic von Frey anaesthesiometer (IITC Life Science, USA). After the test and measurement of the baseline, morphine, gabapentin and some of the aforementioned compounds used according to the invention were administered. The tactile withdrawal thresholds were measured 30 minutes after the administration. The results are expressed as ED50 and % maximal possible effect (% MPE) on the ipsilateral side, in which the baseline is taken as 0% and the withdrawal threshold of a control group is taken as 100% MPE.

[0094]The results together with those from Example 1 are summarized in Table 2:

TABLE 2Testing of the inhibition of neuropathic pain in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
withdrawal thresholdaaaaaaaaaa
withdrawal thresholdaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority from U.S. provisional patent application No. 60 / 906,220, filed Mar. 12, 2007 and Federal Republic of Germany patent application no. DE 10 2007 012 165.4, filed Mar. 12, 2007, the entire disclosures of which are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]The present invention relates to the use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic, preferably mononeuropathic and / or polyneuropathic pain, particularly preferably polyneuropathic pain, and also preferably diabetic neuropathic pain, preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.[0003]The normal physiological pain sensation, which serves as a protective function for the organism, is transmitted via nerve fibres as a response to corresponding painful stimuli. This is referred to as nociceptive pain. Thi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/135A61K31/215A61P25/00
CPCA61K31/137A61P3/10A61P25/00A61P25/02A61P25/04A61P29/00A61P43/00
Inventor CHRISTOPH, THOMASFRIDERICHS, ELMARKOEGEL, BABETTE-YVONNE
Owner GRUNENTHAL GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap